Suven Life Sciences Share Price

Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).As of 25 May 2026, Suven Life Sciences share price is ₹271.01. The stock opened at ₹270.75, compared to its previous close of ₹265.45. During today's trading session, Suven Life Sciences share price moved in the range of ₹265.00 to ₹275.80, with an average price of ₹270.40 for the day. Looking at its last 52-week, the stock has touched a low of ₹265.00 and a high of ₹275.80. On the performance front, Suven Life Sciences share price has increased by 57.64% over the last six months and is up 30.50% on a year-on-year basis.

The market capitalization of Suven Life Sciences is ₹7,015 Crs, with a P/E ratio of -25.4 and a dividend yield of 0.00%.